This inventor holds 5 USPTO granted patents and 6 published patent applications and 2 EPO patents. Top assignees: Harvard College, The Broad Institute, Inc., Massachusetts Institute of Technology. Active years: 2018-2025.
Company Filing History:
5 out of 3,069 
3 out of 480 
2 out of 8,573 
Years Active: 2018-2025
Title: Cameron Myhrvold: Innovator in CRISPR Technology
Introduction
Cameron Myhrvold is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of CRISPR-based technologies. With a total of 5 patents, Myhrvold is recognized for his innovative approaches to antiviral therapies.
Latest Patents
One of Myhrvold's latest patents is titled "CRISPR Effector System Based Diagnostics for Hemorrhagic Fever Detection." This invention offers a novel method for highly multiplexed, programmable antiviral therapies that directly target viral RNA. The technology can be flexibly adapted to address novel viruses or emerging outbreak pathogens. Class 2, type VI CRISPR system-based therapies can be utilized alongside existing antiviral compounds, enhancing their efficacy or preventing the evolution of drug resistance mutations. Notably, if a virus develops resistance to a specific guide RNA sequence, it is straightforward to switch to a different guide RNA sequence or design a new one to target the new mutation. This adaptability is crucial in preventing widespread resistance to these innovative therapies.
Career Highlights
Cameron Myhrvold has worked at prestigious institutions such as Harvard College and The Broad Institute, Inc. His work has been instrumental in advancing the understanding and application of CRISPR technology in medical science.
Collaborations
Myhrvold has collaborated with notable scientists, including Pardis Sabeti and Catherine Amanda Freije. These partnerships have further enriched his research and contributed to the development of groundbreaking technologies in the field.
Conclusion
Cameron Myhrvold is a key figure in the realm of CRISPR technology, with a focus on antiviral therapies. His innovative patents and collaborations highlight his commitment to advancing biotechnology for the betterment of public health.